

**Amendments to the claims:**

Claims 1-15 (Cancelled).

16. (New) Paroxetine maleate in which the molar ratio of paroxetine to maleic acid is 1:1.
17. (New) Paroxetine maleate in which the molar ratio of paroxetine to maleic acid is 2:1.
18. (New) A compound according to claim 16 in non-crystalline form.
19. (New) A compound according to claim 17 in non-crystalline form.
20. (New) A compound according to claim 16 in crystalline form.
21. (New) A compound according to claim 17 in crystalline form.
22. (New) Paroxetine (1:1) maleate Form A having a melting point of 139-141°C and having an IR or XRD spectrum substantially as disclosed in Example 1.
23. (New) Paroxetine (1:1) maleate Form B having a melting point of 136-138°C and having an IR or XRD spectrum substantially as disclosed in Example 2.
24. (New) A process for the preparation of a compound as claimed in claim 16 by precipitation from a solution of a paroxetine maleate, spray drying or freeze drying a solution of a paroxetine maleate, evaporating a solution of a paroxetine maleate to a glass, or by vacuum drying of oils of a paroxetine maleate, or solidification of melts of a paroxetine maleate.
25. (New) A process for the preparation of a compound as claimed in claim 17 by precipitation from a solution of a paroxetine maleate, spray drying or freeze drying a solution of a paroxetine maleate, evaporating a solution of a paroxetine maleate to a glass, or by vacuum drying of oils of a paroxetine maleate, or solidification of melts of a paroxetine maleate.
26. (New) A process for the preparation of a compound as claimed in claim 16 by crystallization or recrystallization from a solution of a paroxetine maleate.
27. (New) A process for the preparation of a compound as claimed in claim 17 by crystallization or recrystallization from a solution of a paroxetine maleate.

28. (New) A process for preparing paroxetine (1:1) maleate Form A by crystallisation from a solution of paroxetine maleate in ethyl acetate, methanol, ethanol, propan-2-ol, propan-1-ol, sec-butanol, butan-1-ol, methyl isobutylketone, acetone or acetonitrile, or a mixture of solvents, including mixtures with toluene.
29. (New) A process for preparing paroxetine (1:1) maleate Form B by crystallisation from a solution of paroxetine maleate in toluene, or butanone, acetone, dichloromethane or propan-2-ol, or a mixture of one of said solvents with toluene.
30. (New) A process according to claim 28 in which the solution is seeded with seed crystals of the desired polymorph.
31. (New) A process according to claim 29 in which the solution is seeded with seed crystals of the desired polymorph.
32. (New) A process according to claim 22 in which the solution, oil or melt of a paroxetine maleate is prepared by treating paroxetine free base or an organic acid salt thereof with maleic acid or an ammonium or amine salt thereof.
33. (New) A process for preparing paroxetine (1:1) maleate Form B in which a solution of paroxetine free base, which is the final stage of a process for manufacturing paroxetine, is treated with maleic acid, and Form B is crystallised from said solution.
34. (New) A process according to claim 33, in which the paroxetine free base, or the resultant maleate is in solution in toluene, or in a solvent mixture containing toluene.
35. (New) A method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a salt of the invention to a sufferer in need thereof.